Title:
【発明の名称】癌の治療および診断
Document Type and Number:
Japanese Patent JP2002513378
Kind Code:
A
Abstract:
The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.
Inventors:
Vander, Neil H
Application Number:
JP50699598A
Publication Date:
May 08, 2002
Filing Date:
July 17, 1997
Export Citation:
Assignee:
CORNELL RESEARCH FOUNDATION, INCORPORATED
International Classes:
G01N33/53; A61K38/00; A61K39/395; A61K45/00; A61P35/00; C07K16/28; C07K16/30; C12N15/09; C12P21/08; C12Q1/02; G01N33/574; C12R1/91; (IPC1-7): A61K39/395; A61K38/00; A61K45/00; A61P35/00; C07K16/28; C12P21/08; C12Q1/02; G01N33/53; G01N33/574
Domestic Patent References:
| JPH08506005A | 1996-07-02 | |||
| JPS62215870A | 1987-09-22 |
Other References:
JPN4007019035, ＭＵＲＰＨＹ， Ｇ．Ｐ． ｅｔ ａｌ．, Ｔｈｅ Ｐｒｏｓｔａｔｅ, 199604, Ｖｏｌ．２８, ｐｐ．２６６−２７１
Attorney, Agent or Firm:
Aoyama Ryo (1 person outside)